

difficult to detect and quantify the Z-isomer alone (14). Because all of the samples in this study were purchased in powder form and handled identically, different E-isomerization in SU5416 provided by different vendors could explain some of the potency variability. Another potential reason for this could be the effect of non-ultraviolet detectable impurities present in the SU5416 supplied by different vendors. Neither the peak areas nor the SU5416 activity in tube assays correlated with the reagent cost. The primary limitation of this study is that potency was determined *in vitro*. However, the large differences in the activity of the same compound from different vendors confirms the previously irrational fears of researchers that despite similar stated purities and associated certifications, the same compound from different vendors is not always the same. Hence, when switching from one SU5416 vendor to another, a benchmark activity assay should be performed to validate and account for potency variation. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Tanmaye Nallan Chakravarthula, M.S.
Indiana University School of Medicine
Indianapolis, Indiana
and
Purdue University
West Lafayette, Indiana

John Zagorski, Ph.D.
Indiana University School of Medicine
Indianapolis, Indiana

Ziqian Zeng, M.S.
Indiana University School of Medicine
Indianapolis, Indiana
and
Purdue University
West Lafayette, Indiana

Jeffrey A. Kline, M.D.
Indiana University School of Medicine
Indianapolis, Indiana

Nathan J. Alves, Ph.D.*
Indiana University School of Medicine
Indianapolis, Indiana
and
Purdue University
West Lafayette, Indiana

ORCID IDs: 0000-0001-7190-3109 (J.A.K.); 0000-0003-3816-5137 (N.J.A.).

*Corresponding author (e-mail: nalves@iu.edu).

References

- Jennens RR, Rosenthal MA, Lindeman GJ, Michael M. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (sunitinib) in a patient with probable von Hippel-Lindau syndrome. *Urol Oncol* 2004;22:193–196.
- Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. *Am J Respir Cell Mol Biol* 2003;29:88–97.
- Strielkov I, Weissmann N. Role of the aryl hydrocarbon receptor in Su5416/hypoxia-induced pulmonary hypertension: a new mechanism for an “old” model. *Am J Respir Cell Mol Biol* 2018;58:279–281.

- Mizuno S, Farkas L, Al Hussein A, Farkas D, Gomez-Arroyo J, Kraskauskas D, et al. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. *Am J Respir Cell Mol Biol* 2012;47:679–687.
- Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GPL, Szulcek R, et al. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2019;200:910–920.
- Kojonazarov B, Hadzic S, Ghofrani HA, Grimminger F, Seeger W, Weissmann N, et al. Severe emphysema in the SU5416/Hypoxia rat model of pulmonary hypertension. *Am J Respir Crit Care Med* 2019;200:515–518.
- Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoepfer MM, Gottlieb J, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. *Am J Pathol* 2011;179:167–179.
- Jiang B, Deng Y, Suen C, Taha M, Chaudhary KR, Courtman DW, et al. Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 2016;54:461–468.
- Kovacs L, Cao Y, Han W, Meadows L, Kovacs-Kasa A, Kondrikov D, et al. PFKFB3 in smooth muscle promotes vascular remodeling in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2019;200:617–627.
- Dannewitz Prosseda S, Tian X, Kuramoto K, Boehm M, Sudheendra D, Miyagawa K, et al. *FHIT*, a novel modifier gene in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2019;199:83–98.
- Dai Z, Zhu MM, Peng Y, Machireddy N, Evans CE, Machado R, et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2 α inhibitor. *Am J Respir Crit Care Med* 2018;198:1423–1434.
- Mirando AC, Abdi K, Wo P, Lounsbury KM. Assessing the effects of threonyl-tRNA synthetase on angiogenesis-related responses. *Methods* 2017;113:132–138.
- Carpentier G, Martinelli M, Courty J, Cascone I. Angiogenesis analyzer for ImageJ. Presented at the 4th ImageJ User and Developer Conference Proceedings. 2012, Mondorf-les-Bains, Luxembourg. pp. 198–201.
- Zhao Y, Sukbuntherng J, Antonian L. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS. *J Pharm Biomed Anal* 2004;35:513–522.

Copyright © 2020 by the American Thoracic Society



Expression of Concern: Mitochondrial-Targeted Antioxidant Therapy Decreases Transforming Growth Factor- β -Mediated Collagen Production in a Murine Asthma Model

The *Journal* has become aware of a duplication contained in a figure published in the January 2015 issue (1). The duplication appears in two panels labeled MT and MT/OVA in Figure 3A in the supplement to the article. The authors were contacted but were unable to locate the original images for that figure. Accordingly, this Expression of Concern is intended to inform readers that some conclusions drawn from the figure may not be valid.

Reference

- Jaffer OA, Carter AB, Sanders PN, Dibbern ME, Winters CJ, Murthy S, Ryan AJ, Rokita AG, Prasad AM, Zabner J, Kline JN, Grumbach IM, Anderson ME. Mitochondrial-targeted antioxidant therapy decreases transforming growth factor- β -mediated collagen production in a murine asthma model. *Am J Respir Cell Mol Biol* 2015;52:106–115.

Copyright © 2020 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).